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Kallikrein excretion in renal transplant recipients and uninephrecto-
mized donors. The rate of tissue kallikrein (EC 3.4.21.35) excretion into
the urine has been examined with an active site-specific radio-
immunoassay for kallikrein in renal transplant recipients, in post-
uninephrectomy kidney donors, and in a normal control population.
Normal individuals on uncontrolled diets excreted 96.88 7.00 (sEM)
.tg of active kallikrein/24 hr and 113.68 8.39 g of total kallikrein/24
hr, as determined after trypsin treatment of urine samples. Uninephrec-
tomized donors secreted significantly less (P < 0.05) active (44.99
6.39 tgI24 hr) and total (73.59 11.95 .tg/24 hr) kallikrein than either
the entire normal population or an age-matched subpopulation. Recip-
ients with good renal function who had received kidneys 2 to 13 years
prior to kallikrein assay excreted less (P < 0.05) active (13.21 2.50
pgI24 hr) and total (18.69 3.65 .tg/24 hr) kallikrein than either normal
or uninephrectomized populations. Similar values for active (11.05
1.56 ,ug/24 hr) and total (17.60 1.96 sg/24 hr) kallikrein were seen in
patients who had received kidneys within 6 months of assay. Thus,
kallikrein excretion in kidney recipients remains significantly lower
than in uninephrectomized donors. As compared to normal individuals,
the reduced kallikrein excretion in post-uninephrectomized kidney
donors and in renal allograft recipients suggests that renal kallikrein
excretion may reflect functional distal tubular mass.
Excretion de kallikréine chez des receveurs de transplant renal et chez
des donneurs uninéphrectomisés. La vitesse d'excrétion urinaire de la
kallikréine (EC 3.4.21.35) tissulaire a été examinée avec un radioim-
munoessai spécifique du site actif de Ia kallikréine chez des receveurs
de transplant renal, chez des donneurs de rein après uninephrectomie,
et dans une population contrôle normale. Des individus normaux en
régime non contrôlé excrétaient 96,88 7,00 (sEM) g de kallikréine
active/24 hr et 113,68 8,39 g de kallikréine totale/24 hr, déterminée
après traitement par Ia trypsine des échantillons d'urines. Les donneurs
uninéphrectomises sécrétaient significativement moms (P < 0,05) de
kallikréine active (44,99 6,39 j.g/24 hr) et totale (73,59 11,95 jsg/24
hr) que Ia population normale dans son entier ou qu'une souspopulation
appariee en fonction de l'hge. Les receveurs dont Ia fonction rénale est
bonne qui avaient recu un rein 2 a 13 ans avant le dosage de kallikréine,
excrétaient moms (P < 0,05) de kallikréine active (13,21 2,50 g/24
hr) et totale (18,69 3,64 g/24 hr) que les populations normales ou
uninéphrectomisées. Des valeurs semblables de kallikréine active
(11,05 1,56 jg/24 hr) et totale (17,60 1,96 g/24 hr) ont été
observées chez des malades qui avaient recu un rein dans les 6 mois
avant le dosage. Ainsi, l'excrétion de kallikréine chez les receveurs de
rein demeure significativement plus faible que chez les donneurs
uninéphrectomisés. Par rapport a des individus normaux, l'excrétion
reduite de kallikréine chez les donneurs de rein après unmnéphrectomie
et chez des receveurs d'allogreffe rénale suggere que l'excrétion rénale
de kallikréine pourrait réfléter Ia masse tubulaire distale fonctionnelle.
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Kininogenases or kallikreins are enzymes that share the
capacity to release vasoactive kinin polypeptides from their
plasma kininogen substrates. Glandular (tissue) kallikreins (EC
3.4.21.35), which are found in kidney, pancreas and salivary
glands and their secretions, are structurally, functionally, and
antigenically different from plasma kallikrein (EC 3.4.21.34)
(reviewed in [1]), but are related to each other by the same
criteria in humans [1—3] and other mammals [4, 5]. The tissue
kallikrein found in the urine of the rat is thought to be
synthesized intrarenally based on in vitro studies [6]. Func-
tional and immunohistochemical localization studies [7—11]
suggest that urinary kallikrein is synthesized at the level of the
distal convoluted tubule and secreted into the tubular lumen.
Enzymatically active glandular kallikrein has been found also in
human plasma by immunoaffinity chromatography [12]; plasma
concentrations determined for glandular kallikrein by radio-
immunoassay are 10—15 nglml in humans [13], 10—20 nglml in
the pig [13], and 47 ng/ml in the rat [14]. These low levels of
circulating antigen likely originate from salivary [141 or pancre-
atic sources and are reabsorbed from the glomerular filtrate in
the proximal tubules, as suggested by the additional immuno-
histochemical localization of glandular kallikrein antigen in
proximal tubule reabsorption droplets in the human [11] or rat
[10] kidney. Renal kallikrein may play a role in salt and water
handling by the kidney (reviewed in [15]). Some studies have
shown TAMe (p-tosyl-barginine methyl ester) esterase activity
and kallikrein antigen to be diminished in urine from patients
with essential hypertension [16—18], although this reduction
may be the result of renal tubular damage associated with the
disease process rather than a causative agent or predisposing
factor [19].
Because secretion of intrarenally synthesized kallikrein into
the urine at the level of the distal convoluted tubule may be a
marker of renal tubular function independent of glomerular
filtration, measurement of urinary kallikrein could be a useful
indicator of tubular function in renal transplant recipients.
Previous studies with an in vivo vascular perfusion assay [20] or
with in vitro assays using small synthetic substrates [21—23]
have yielded conflicting data about urinary kallikrein excretion
in post-transplant patients, particularly in association with
rejection episodes where either decreased [20, 22, 23] or in-
creased [21] kallikrein excretion has been reported. The differ-
ences in these data may arise at least in part from the use of
assays that are not specific for urinary kallikrein, thus leading to
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Table I. Source of assay samples for active and total urinary kallikrein
Sex°
N
Age
years
(mean and range)
Race'
N
Samples
assayed
N
Control groups
Uninephrectomized donors M6,F8 59.3 C14 14N 14 (31to79)
Normals
Fresh urine M18,F18 39.3 C33,B2,Ol 46N=36 (18to72)
Frozen urine M4,F3 35.4 C7 29N=7 (16to69)
Patient groups
Short-term recipients, 0 to 6 mo M19,F10 38.8 C27,B1,O1 122N=29 (17to60)
Long-term recipients, 2 to 13 yr M2,F6 39.6 C8 18N=8 (30to54)
a M = male, F = female.b C = Caucasian, B = Black, 0 Oriental.
detection of other unrelated urinary enzymes [24—26] or to
measurement of plasma enzymes with similar activities in the
urine of patients with proteinuria. The present study describes
the application of a specific radioimmunoassay for human tissue
kallikrein [27] to the evaluation of urinary kallikrein excretion in
individuals who had received single renal allografts one day to
13 years prior to assay. In contrast to previous studies of
kallikrein excretion by renal transplant recipients 120—23, 26],
kallikrein antigen was measured also in a uninephrectomized
donor population. The data obtained support experimental
studies in the rat that suggest that post-uninephrectomy adap-
tive renal hypertrophy is a selective phenomenon, because of
all segments of the nephron the distal tubule, which is the site of
renal kallikrein secretion [7—11], shows the least hypertrophy
[28].
Methods
Patient and control groups
Age, sex, race, and size of each of the patient and control
groups examined are shown in Table 1. Potential kidney do-
nors, hospitalized while undergoing evaluation of their renal
function, served as normal controls. Forty-six 24-hr urine
volumes were stored at 4°C and assayed for urinary kallikrein
within 24 hr of completion of the collection. Twenty-nine 24-hr
urine samples obtained from other normal individuals were
stored at —70°C until samples were assayed for kallikrein.
Fourteen otherwise healthy individuals who had donated a
single kidney 10 to 20 years (mean = 14 years) prior to urine
collection for kallikrein assay were examined on an outpatient
basis. Urine samples were stored at 4°C during the 24-hr
collection period and samples were frozen at —70°C until assay.
Blood pressures were determined as the mean of three separate
readings at the end of the collection period. For all individuals,
serum creatinine and urinary sodium, potassium, and creatinine
were measured in samples obtained at the time of urine collec-
tion for kallikrein assay.
Kallikrein excretion was determined in both long-term and
short-term kidney recipients. The former group had received
kidneys between 2 and 13 years (mean = 5.4 years) previously,
were on maintenance azathioprene and steroid therapy, and
were judged to have satisfactory renal function on the basis of
stable serum creatinine (Cr < 2.5 mg%) levels, The urine
samples obtained on an outpatient basis were stored at 4°C
during the 24-hr collection period and samples were assayed for
kallikrein within two days after the completion of collection or
were frozen at —70°C until assay. Twenty-four-hr urine samples
were obtained also from inpatients hospitalized for reasons
other than management of rejection episodes; these samples
were stored at 4°C and assayed within two days of completion
of the collection. Serum creatinine was measured on the day of
urine collection and urinary creatinine, sodium, and potassium
were determined concurrently. Samples from short-term recip-
ients were collected at times ranging from the first post-
operative day to six months after surgery and examined as
described above. Twelve patients received kidneys from living
related donors and 17 received cadaver kidneys. Of this second
group, 12 were on maintenance immunosuppresion with cyclo-
sporine and steroids; the remaining five and the recipients of
living related donor kidneys were on maintenance azathioprene
and steroids. Three or more sequential samples were obtained
from 18 of these patients, and pre-transplant samples ranging
from 390 to 1700 mIs were obtained from four of them.
Assays
Routine urinary creatinine, sodium, and potassium assays
were performed by Bioran Medical Laboratory, Inc. (Boston,
Massachusetts, USA), and serum creatinine was determined in
the clinical laboratory at Brigham and Women's Hospital,
Boston, Massachusetts, USA. Glomerular filtration rates
(GFR) were calculated on the basis of creatinine clearance.
Active urinary kallikrein was measured by radioimmunoassay
[27] using as the primary antibody an IgG fraction from an
antiserum shown previously to recognize antigenic determi-
nants at or near the active enzymatic site of urinary and
pancreatic kallikreins [3, 29, 301. Total kallikrein was deter-
mined by radioimmunoassay after trypsin treatment of the urine
as described [27]. For each value determined, duplicate samples
of three volumes (usually 10, 25, and 50 d) were assayed and
kallikrein concentrations were determined with a standard
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Table 2. Comparison of renal function and kallikrein excretion in
post-uninephrectomy renal donors and selected normal populations
Post-
uninephrectomy
Renal donors
Normal populations
All normals Age-matchedN=14 N=75 N=14
GFR (Ccr), 73.02 7.91 100.75 3.30 98.01 9.67
mi/mm (P < 0.01) (Ns)
Active kallikrein, 44.99 6.39 96.88 7.00 103.12 14.62
p.g/24 hr (P < 0.01) (P < 0.0005)
Total kallikrein, 73.59 11.95 113.68 8.39 117.89 14.81
sg/24 hr (P < 0.05) (P < 0.05)
N = number of samples.
Values are mean SEM and significance levels are relative to the
post-uninephrectomy donor group.
curve prepared with purified urinary kallikrein [31] diluted
serially in kallikrein-free urine [271. The mean of all six deter-
minations was normalized to 1 ml and used to calculate the
24-hr excretion rate.
Statistics
Values are expressed as mean the SEM. Linear regression
analyses, assessment of distribution normality, and Wilcoxon
rank sum tests for non-normally distributed sample groups were
assisted by the Clinfo Data Computer Center at the Brigham
and Women's Hospital. Unpaired t tests for comparison of
normally distributed sample groups were performed at the
Clinfo Center or with the aid of a statistics calculator (Hewlett
Packard 9805A, Loveland, Colorado, USA). The null hypoth-
esis was rejected for P 0.05.
Results
Control groups
Because it was necessary to use both fresh and frozen urine
samples from the renal allograft recipient groups, the determi-
nation of urinary kallikrein excretion was examined in two
groups of normals using fresh or frozen urine. Although the
mean 24-hr urine volumes obtained from the two groups were
significantly different, there was no statistically significant
difference in the daily excretion rate of Na, K4, or creatinine,
in serum creatinine or GFR. Active and total kallikrein were not
significantly different when measured in fresh versus frozen
urine, and there was no significant correlation between active or
total kallikrein and the parameters of renal function mentioned
above (r ranged from — 0.237 to + 0.179).
To compare the kallikrein excretion rate of kidney recipients
to that of a reference population with single kidneys, active and
total kallikrein excretion was determined in urine from unine-
phrectomized kidney donors (Table 2). When compared to the
entire normal population examined, the active and total kal-
likrein excretion rates were significantly lower in the single
kidney group. Because the mean age of the post-nephrectomy
donor group was significantly greater (59.3 years) than that of
the control group (37.4 years), a subgroup of ii age-matched
normals was compared to the kidney donor group. Fourteen
samples were examined in eight female and three male subjects
having a mean age of 55.9 years. Their mean active kallikrein
Table 3. Correlation of active and total kallikrein excretion with other
parameters of renal function in post-uninephrectomy kidney donors
Parameter examined
Correlation with excretion of
Active kallikrein Total kallikrein
(Mean SEM) r r
Serum creatinine
1.33 0.10 mg/100 ml —0.036 —0.097
Urinary volume
1471.1 94.31 m1124 hr 0.358 0.187
Urinary creatinine
1.33 0.13 gm/24 hr 0.523 0.742a
GFR (Ccr)
73.02 7.91 mI/mm 0.430 0.658a
Urinary Na
116.77 12.39 mEq/24 hr 0.188 0.294
Urinary K
70.07 7.55 mEq/24 hr 0.693 0.817a
Years post uninephrectomy
13.5 0.93 years 0.030 —0.010
Abbreviation: r, correlation coefficient.
a Statistically significant at P < 0.05.
and total kallikrein were significantly higher also than the values
from the post-nephrectomy donor group and not different from
the entire normal control group (Table 2). However, glomerular
function in the post-nephrectomy donors, determined as creat-
mine clearance, was not significantly lower than that in the
age-matched controls, although it was lower than that seen in
the composite normal control group (Table 2).
In the post-nephrectomy donor group, there was no signifi-
cant correlation between active or total kallikrein excretion and
serum creatinine, 24-hr urine volume, sodium excretion, or
years since uninephrectomy (Table 3). In this group only, total
kallikrein excretion correlated moderately well with urinary
potassium (r = 0.817), creatinine (r = 0.742), and GFR (r =
0.658). Since six of the uninephrectomized controls were mildly
hypertensive (diastolic pressures between 90 and 103 mm Hg),
their kallikrein excretion rates were compared to those of the
normotensive subgroup of eight. Neither active kallikrein (47.77
13.82 vs. 41.65 6.47 g/24 hr) nor total kallikrein (88.03
23.04 vs. 62.76 11.92 tg/24 hr) were significantly different for
hypertensives and normotensives, respectively.
Renal allograft recipients
When compared to either the normal controls or the
uninephrectomized kidney donors, long-term kidney recipients
with satisfactory renal function who had received organs 2 to 13
years previously excreted significantly less active kallikrein
(13.21 2.50 j.g/24 hr; P < 0.001) and total kallikrein (18.69
3.64 g/24 hr; P < 0.001) (Table 4). There were an insufficient
number of cadaver kidney recipients (N = 2) to permit statis-
tical comparison of their kallikrein excretion with that of
recipients of living related donor kidneys (N = 6). When the
other parameters of renal function examined were compared to
kallikrein excretion, the only significant positive correlation
found was with sodium excretion (Table 4).
Kidney recipients who had received organs within six months
of testing excreted 11.05 1.56 g of active kallikrein/24 hr and
17.60 1.96 g of total kallikrein/24 hr. As analyzed by the
Wilcoxon rank sum test, these values were significantly less
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Table 4. Correlation of active and total kallikrein with other
parameters of renal function in long-term kidney recipients with
stable renal function
Parameter examined
Correlation with
Active kallikrein Total kallikrein
(Mean SEM) r r
Serum creatinine
1.78 0.10 mg/l00 ml 0.322 0.452
Urine volume
1597.40 179.88 m1124 hr 0.060 0.287
Urine creatinine
0.85 0.09 g124 hr —0.149 —0.245
GFR
33.31 5.88 mI/mm —0.472 —0.609
Urine Na
109.53 22.98 mEq/24 hr 0.717a Q•779a
Urine K
32.86 4.72 mEqI24 hr 0.284 0.390
Active kallikrein
13.21 2.50 g/24 hr —
Total kallikrein
18.69 3.64 g/24 hr — —
Years post transplant
4.94 1.46 —0.09 —0.05
N = 18 samples.
Abbreviation: r, correlation coefficient.
a Significant at P < 0.05.
than active and total kallikrein excretion by post-nephrectomy
donors (P < 0.001). Active kallikrein, but not total kallikrein,
was also significantly lower when compared to long-term kid-
ney recipients with stable renal function (P < 0.03). Active and
total kallikrein excretion did not correlate well with any of the
other parameters of renal function examined (Table 5). For four
patients in this group, pretranspiant donor and recipient urines
were available for analysis also. No detectable active kallikrein
was excreted by these four pretransplant recipients in urine
volumes ranging from 390 to 1700 ml/24 hr; and the total
kallikrein level in this group was 1.72 0.74 g/24 hr. The four
prenephrectomy donors excreted 92.40 19.04 g of active
kallikrein and 129.86 30.16 tg of total kallikrein/24 hr. When
examined at 4 or 5 days after transplant, the recipients excreted
23.93 4.77 tg of active kallikrein and 44.75 10.42 g of total
kallikrein/24 hr.
Active and total kallikrein were not statistically correlated
with serum creatinine and GFR when examined sequentially in
kidney recipients (Table 5). To examine the possibility that
elevated kallikrein excretion rates preceded or were associated
with rejection episodes [21], recipients whose total kallikrein
excretion rates were within one standard deviation of the mean
of the post-nephrectomy donor group (> 28 g/24 hr) were
assessed with regard to renal function at the time of sampling
and at one week after sampling. (Seven additional patients from
whom only one sample was obtained within six months of
kidney implantation were included in this group.) Of the 32
samples from 21 recipients containing total kallikrein values
greater than 28 g/24 hr, close to two-thirds of the samples
(62.5%) were obtained from clinically stable patients. The
remainder of the samples were obtained when some of these
individuals showed increasing serum creatinine levels, were
Table 5. Correlation of active and total kallikrein with other
parameters of renal function in short-term kidney recipients
Parameter examined
Correlation with
Active kallikrein Total kallikrein
(Mean 5EM) r r
Serum creatinine
4.70 0.40 mg/100 ml —0.265 —0.315
Urine volume
2030 92.28 ml/24 hr 0.190 0.297
Urinary creatinine
1.13 0.05 g/24 hr 0.219 0.229
GFR (CCr)
33.70 3.16 mI/mm 0.401 0.383
Urinary Na
100.12 10.89 mEq/24 hr 0.170 0.197
Urinary K
44.67 2.96 mEq/24 hr 0.293 0.302
Active kallikrein
11.05 1.56 g/24 hr — —
Total kallikrein
17.60 1.96 p.g/24 hr — —
N = 122 samples.
Abbreviation: r, correlation coefficient.
Table 6. Summary of active and total kallikrein excretion in control
and allograft recipient groups
Composite Uninephrec-
normal tomized Renal allograft
group donors recipients2tol3yr Oto6mo
Active kallikrein 96.88 4499 1321b 1105b.c
g/24 hr
Total kallikrein 113.68 7359a
1.56
1869b 1760b,d
pg/24hr
a Significantly different from composite normal group (P < 0.05).
b Significantly different from uninephrectomized donor and normal
groups (P < 0.001).
Significantly different from long-term recipients (2 to 13 yr) with
stable renal function as determined by Wilcoxon rank sum analysis (P
<0.03).
d Notdifferent from long-term recipients as determined by Wilcoxon
rank sum analysis (P < 0.05).
receiving steroid pulses for rejection episodes, or were recov-
ering from rejection episodes.
Discussion
To evajuite the utility of kallikrein excretion as a marker of
renal tubular function independent of glomerular filtration,
urinary kallikrein has been measured by specific radioimmuno-
assay in renal transplant recipients and compared to their renal
function and to the kallikrein excretion levels obtained in one-
and two-kidney control groups. The mean total (active plus
trypsin-activatable) kallikrein obtained by radioimmunoassay
for the composite population of normal individuals with two
kidneys (Table 6) is similar to the control values of 127 to 136
g/24 hr determined for normotensive individuals taking 180 or
40 mEq sodium diets [32, 33] in a radioimmunoassay that
measures directly total kallikrein 1341. Other groups have noted
total kallikrein excretion rates of 155, 209 or 242 g/24 hr in
normals on 109 mEq sodium diets with radioimmunoassays that
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measure total kallikrein directly [35] or after trypsin activation
[36, 37]. These higher values may reflect the smaller size,
younger age, controlled diets, or sodium-balanced state of the
populations studied or the standardization of the various
radioimmunoassays. Since all but two individuals in the normal
population and all but one patient were Caucasian (Table 1),
none of the present results can be ascribed to lower kallikrein
excretion in a Black population [18]. Active kallikrein antigen
levels of 114, 155 and 248 g/24 hr have been reported for a
group of four individuals each given 259, 109 and 9 mEq sodium
diets [37, 38]. Excretion rates of 107 Lg/24 hr have been
reported for a normal population on uncontrolled diets with a
radioimmunoassay presumed to recognize total kallikrein [26].
Latent (total minus active) kallikrein represents 14 to 16% of the
total in the two-kidney control groups (Table 2), similar to the
22% value calculated from the 24-hr active and trypsin-activa-
table kallikrein antigen data of Shimamoto, Chao, and
Margolius 137]. Calculating from the data of Lieberthal et al
[32], where active kallikrein was measured by the capacity to
generate kinin antigen and total kallikrein was measured by
radioimmunoassay, latent kallikrein ranged from 21% to 66% in
groups subjected to a variety of physiologic manipulations. In
the experimental groups described herein, controlled dietary
conditions were not feasible, which may explain the lack of
inverse relationship between sodium and kallikrein excretion
[18, 32, 39]. Because samples from allograft recipients and
donors, and thus from normal controls also, were obtained from
individuals on random diets, little emphasis will be placed on
the ratios of active to total kallikrein excretion.
The single-kidney donor post-uninephrectomy group ex-
creted significantly less active and total kallikrein than either
the composite normal population (Table 6) or an age-matched
subgroup (Table 2). Since there was no correlation between
kallikrein and sodium excretion in any of these groups on
uncontrolled diets, it is not possible to explain the lower
kallikrein excretion rate of the uninephrectomized donors on
the basis of their higher mean sodium excretion (56.19 7.59
vs. 116.77 12.59 mEq/24 hr). Although the filtration function
in post-nephrectomy donors, as determined by creatinine clear-
ance, did not differ from that of the age-matched controls (Table
2) [40, 41], active and total kallikrein excretion were, respec-
tively, 45 and 60% of the control group. When compared to the
excretion rate per single kidney in the age-matched normal
group, the uninephrectomized donors excreted 87% of the
active kallikrein and 125% of the total kallikrein of the controls.
These results, together with the unaltered GFR (Table 2),
suggest that kallikrein excretion is independent of glomerular
filtration per se and that post-uninephrectomy adaptive renal
hypertrophy may affect glomerular filtration and tubular trans-
port functions [28, 42] to a greater extent than tubular synthetic
function. Thus, kallikrein excretion rate might be a useful
indicator of functional distal tubular mass. These results sup-
port also the studies showing that urinary kallikrein is synthe-
sized within the kidney [6, 43], rather than entirely representing
filtered pancreatic and salivary kallikrein [44]. Because some
kidney donors may develop minimal hypertension several years
after nephrectomy [41] and because some studies have found an
association between essential hypertension and diminished
kallikrein excretion [16, 17], data from normotensive and hyper-
tensive post-nephrectomy donors were examined separately.
There was no difference in active and total kallikrein excretion
between the two subgroups, suggesting that the tubular mass
remaining in the hypertensive subgroup had not been damaged
with regard to its capacity to synthesize and secrete kallikrein
[19]
Active and total kallikrein excretion were significantly de-
creased in both groups of renal transplant recipients (Tables 4
and 5) as compared to uninephrectomized kidney donors (Table
6). In contrast to an earlier study measuring TAMe cleavage
1291, kallikrein antigen values did not increase progressively to
normal levels (Table 3). Recipients who had received kidneys 2
to 13 years prior to study excreted active and total kallikrein at
a rate approximately 25% that of uninephrectomized donors,
while filtration function was 46% that of the donor group. This
finding is consistent with the suggestion that the low
kininogenase excretion rate in renal allograft recipients may in
part be due to a loss of neuronal regulation [45],which is known
to participate in salivary glandular kallikrein secretion 1461.
Kallikrein excretion rates were not elevated predictably in
association with or prior to rejection episodes. This finding and
a recent report that urinary amidolytic activity, but not kal-
likrein antigen, is increased in association with rejection [26]
indicate that the increased TAMe esterase activity found during
rejection [21] represents enzymes other than urinary kallikrein.
The small group of normotensive transplant recipients (N= 5)
did not excrete significantly more active kallikrein (4.75 1.10
vs. 11.05 1.56 g/24 hr) or total kallikrein (8.27 2.44 vs.
17.60 1.96 ag/24 hr) than the entire transplant population.
There was no statistically significant difference in either active
kallikrein (13.31 2.23 vs. 8.90 2.14 gIml) or total kallikrein
(19.48 2.86 vs. 14.56 2.54 gIml) when values from
recipients of living related donor kidneys were compared with
values from recipients of cadaver kidneys. In the four instances
where pretransplant urine was obtained, almost no measurable
kallikrein was observed, while 4 to 5 days after kidney trans-
plantation, mean values of 24 and 45 Lg/24 hr of active total
kallikrein, respectively, were measured. These results support
further the role of the kidney in the synthesis of urinary
kallikrein as suggested in an earlier study of renal transplant
patients [23] and indicate that determination of urinary kal-
likrein excretion by specific immunoassay may be a useful
direct measure of distal tubular mass or function.
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